Literature DB >> 12373085

Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura.

Junya Kuroda1, Shinya Kimura, Yutaka Kobayashi, Katsuya Wada, Nobuhiko Uoshima, Toshikazu Yoshikawa.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) and primary myelodysplastic syndrome (MDS) are hematological disorders that are frequently associated with thrombocytopenia, and both are heterogeneous disorders of uncertain etiology. Their diagnosis requires the exclusion of other hematological or immunological disorders whose diagnosis is usually not difficult. However, in some patients presenting with thrombocytopenia, the differential diagnosis is complex. We performed a retrospective study of 47 consecutive patients treated between 1990 and 2001; in 25 patients the initial diagnosis was ITP, in 22 it was MDS; we compared their backgrounds, laboratory data and clinical outcomes. Among the 25 ITP patients, there were 5 confusing cases. Following treatment, they presented with inexplicable refractory anemia and/or neutropenia. Cytopenia, the polyploidization pattern of megakaryocytes, and chromosomal aberrations were of diagnostic relevance in these patients' defective hematopoiesis. Their cytopenia progressed relatively slowly and none progressed to leukemic transformation. We suggest that these 5 patients should be classified into an unusual subtype of MDS with clinical characteristics resembling ITP. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12373085     DOI: 10.1159/000064703

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  8 in total

1.  Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura.

Authors:  Jun Qian; Yongquan Xue; Jinlan Pan; Jiannong Cen; Wei Wang; Zixing Chen
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.

Authors:  Julie Waisbren; Shira Dinner; Jessica Altman; Olga Frankfurt; Irena Helenowski; Juehua Gao; Brandon J McMahon; Brady L Stein
Journal:  Int J Hematol       Date:  2016-08-24       Impact factor: 2.490

3.  Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Authors:  Qiu-Sha Huang; Jing-Zhi Wang; Ya-Zhen Qin; Qiao-Zhu Zeng; Qian Jiang; Hao Jiang; Jin Lu; Hui-Xin Liu; Yi Liu; Jing-Bo Wang; Li Su; Hong-Yu Zhang; Zhen-Ling Li; Su-Jun Gao; Bo Huang; Yu-Ying Liu; Yan-Rong Liu; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-11-12

4.  Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Authors:  Panagiotis T Diamantopoulos; Maria Michael; Olga Benopoulou; Efthymia Bazanis; George Tzeletas; John Meletis; George Vayopoulos; Nora-Athina Viniou
Journal:  Virol J       Date:  2012-01-03       Impact factor: 4.099

5.  An Acute Leukaemia Masquerading as Immune Thrombocytopaenic Purpura (ITP)? A Case Report.

Authors:  J A Olaniyi
Journal:  Clin Med Case Rep       Date:  2009-04-17

6.  Presence of Essential Hypertension or Diabetes Mellitus Is a Predictor of Intracranial Bleeding in Elderly Patients: A Study of 108 Patients with Isolated Thrombocytopenia from a Single Reference Center.

Authors:  Rajan Kapoor; Hara Prasad Pati; Manoranjan Mahapatra; Anuradha Monga
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

Review 7.  How to interpret and pursue an abnormal complete blood cell count in adults.

Authors:  Ayalew Tefferi; Curtis A Hanson; David J Inwards
Journal:  Mayo Clin Proc       Date:  2005-07       Impact factor: 7.616

Review 8.  When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis.

Authors:  Nicolas Bonadies; Alicia Rovó; Naomi Porret; Ulrike Bacher
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.